Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Friedrich

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Inflammatory Bowel Diseases|August 12, 2015
Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype StatusJohannes Stallhofer, Matthias Friedrich, Astrid Konrad-Zerna, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2008
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humansMaria Amann, Matthias Friedrich, Petra Lutterbuese, et al.
Molecular Cancer Therapeutics|February 26, 2021
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIIIAlexander Sternjak, Fei Lee, Oliver Thomas, et al.
Clinical Pharmacology and Therapeutics|September 16, 2024
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell EngagerDi Zhou, Roman Kischel, Sabine Stienen, et al.
Plos One|October 27, 2010
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cellsInes Herrmann, Patrick A Baeuerle, Matthias Friedrich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2020
The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 ArmFrans V Suurs, Grit Lorenczewski, Sabine Stienen, et al.
Nanoscale|February 14, 2012
Microwave-hydrothermal synthesis and characterization of nanostructured copper substituted ZnM2O4 (M = Al, Ga) spinels as precursors for thermally stable Cu catalystsFranziska Conrad, Cyriac Massue, Stefanie Kühl, et al.
Plos One|November 4, 2014
The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067Fabian Schnitzler, Matthias Friedrich, Christiane Wolf, et al.
Plos One|July 7, 2015
The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 MutationsFabian Schnitzler, Matthias Friedrich, Christiane Wolf, et al.
Plos One|July 28, 2020
Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgeryFabian Schnitzler, Matthias Friedrich, Marianne Angelberger, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Inflammatory Bowel Diseases|August 12, 2015
Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype StatusJohannes Stallhofer, Matthias Friedrich, Astrid Konrad-Zerna, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2008
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humansMaria Amann, Matthias Friedrich, Petra Lutterbuese, et al.
Molecular Cancer Therapeutics|February 26, 2021
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIIIAlexander Sternjak, Fei Lee, Oliver Thomas, et al.
Clinical Pharmacology and Therapeutics|September 16, 2024
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell EngagerDi Zhou, Roman Kischel, Sabine Stienen, et al.
Plos One|October 27, 2010
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cellsInes Herrmann, Patrick A Baeuerle, Matthias Friedrich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2020
The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 ArmFrans V Suurs, Grit Lorenczewski, Sabine Stienen, et al.
Nanoscale|February 14, 2012
Microwave-hydrothermal synthesis and characterization of nanostructured copper substituted ZnM2O4 (M = Al, Ga) spinels as precursors for thermally stable Cu catalystsFranziska Conrad, Cyriac Massue, Stefanie Kühl, et al.
Plos One|November 4, 2014
The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067Fabian Schnitzler, Matthias Friedrich, Christiane Wolf, et al.
Plos One|July 7, 2015
The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 MutationsFabian Schnitzler, Matthias Friedrich, Christiane Wolf, et al.
Plos One|July 28, 2020
Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgeryFabian Schnitzler, Matthias Friedrich, Marianne Angelberger, et al.
Pageof 9